Shanghai Cingular Biotechnology Co., Ltd., founded in October 2010, is located in Shanghai International Medical Zone. It is a high-tech enterprise dedicated to the research and development, production and sales of biomaterial product and implantable medical devices. It is founded by Mr. Jun Yang, a member of the ISO5840 Standard Committee and a PhD. of medicine and bioengineering. The research team consists of many Chinese and American experts. The company now has 2000 square meters of clean area of 10,000 grade and 100,000 grade which meets GMP requirements and is EN ISO 13485: 2016 system certified. Five invention patents (PCT China and International) were granted. The registered capital is around 20 million yuan, and the actual research and development investment is more than 200 million yuan.
Based on independent innovation, the company focuses on the surgical valve replacement and repair with biomaterial technology, as well as focuses on the cardiovascular disease treatment field such as transcatheter valve, and has become a leading high-tech enterprise in the industry. At present, the approved and marketed products include bovine pericardial heart valve prosthesis and dural biological patch. Many other products are in research and clinical trial phases. Cingular Corporation continuously introduces high-quality products with excellent performance and affordable prices to the market, which will benefit the vast number of patients, improve their quality of life and enhance the value of health economics.